Trial Profile

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisagenlecleucel (Primary) ; Tocilizumab
Indications Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms ELARA
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

16 May 2025 Planned End Date changed from 22 May 2025 to 13 May 2025.
12 Apr 2024 Last checked against European Clinical Trials Database record.
29 Feb 2024 Results from ELARA and ZUMA-5, comparing efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methodspublished in the Leukemia and Lymphoma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com